The unprecedented COVID-19 pandemic spanning over three years claimed millions of lives worldwide and caused immense misery to the humanity. Rapid developments of vaccines...
A new global network of laboratories for coronaviruses, CoViNet, has been launched by WHO. The aim behind this initiative is to bring together surveillance...
JN.1 sub-variant whose earliest documented sample was reported on 25 August 2023 and which was later reported by the researchers to have higher transmissibility and immune...
Spike mutation (S: L455S) is hallmark mutation of JN.1 sub-variant which significantly enhances its immune evasion capability enabling it to effectively evade Class 1...
Spikevax Bivalent Original/Omicron Booster Vaccine, the first bivalent COVID-19 booster vaccine developed by Moderna has received MHRA approval. Unlike the Spikevax Original, the bivalent version...
Coronaviruses and influenza viruses are sensitive to acidity of aerosol. pH-mediated rapid inactivation of coronaviruses is possible by enriching the indoor air with non-hazardous...
Cases of co-infections with two variants were earlier reported. Not much was known about viral recombination yielding viruses with hybrid genomes. Two recent studies report...
WHO has updated its living guidelines on COVID-19 therapeutics. The ninth update released on 03 March 2022 include a conditional recommendation on molnupiravir.
Molnupiravir has...
Omicron BA.2 subvariant seems to be more transmissible than BA.1. It also possesses immune-evasive properties that further reduce the protective effect of vaccination against...